And whether you know...
Nimodipin, microscopic cellulose, povidone, monohydrate of lactose, corn starch, magnesium stearate, krospovidon, titanium dioxide, macrogoal, triacetate of a glitserol, iron oxide yellow indigo carmine.
Tablets of 30 mg in a film cover, a round form with a two-convex surface of yellow color in the blister packaging in a cardboard pack No. 30.
Neuroprotective, anti-aggregation, vazodilatiruyushchy.
Pharmacodynamics and pharmacokinetics
Drug, derivative dihydropyridine, belongs to group of blockers of calcium channels. Blocks process of receipt of calcium ions through a cellular membrane. Has vasodilating effect, mainly, on brain vessels.
Stops a vasospasm, causes the expressed increase in blood supply in ishemirovanny sites of a brain. Improves cerebral blood circulation, function of brain neurons at subarachnoidal hemorrhage. Improves ability to concentration of attention and memory. On system the ABP also has no significant effect on contractility of a myocardium.
Fast and almost full absorbability from a gastrointestinal tract. Communication with blood proteins at the level of 95%. An elimination half-life — 10 hours. It Biotransformirutsya in a liver with to level pharmacological of inactive metabolites. It is removed through intestines and it is insignificant in not changed look through kidneys.
Indications to use
In complex therapy of cerebrovascular insufficiency, residual symptoms of disturbance of cerebral circulation, brain ischemia at subarachnoidal hemorrhage.
The expressed arterial hypertension, high sensitivity to drug, pregnancy, a lactation, age till 18 flyings.
Dryness in a mouth, a headache, discomfort in a gastrointestinal tract, nausea, appetite increase, a hyperplasia of gums, diarrhea, decrease in the ABP, stenocardia, bradycardia, an ekstrasistoliya, arrhythmias, an adynamy, dizziness, extrapyramidal disturbances, excitement, the increased psychomotor activity, sleeplessness, an aggression/depression, drowsiness, increased fatigue, cough, difficulty of breath, skin rash, an agranulocytosis, puffiness and morbidity of joints, increase of weight, depression of function of kidneys.
Nimodipin, application instruction (Way and dosage)
Pill is taken inside, without chewing, washing down with water (it is necessary to avoid joint reception with grapefruit juice). Administration of drug is not connected with meal. Time between receptions of tablets has to be not less than 4 hours. The standard recommended dose makes 30 mg three times a day. The course of treatment is defined individually and can proceed for several months.
At administration of drug in the doses exceeding therapeutic are possible: nausea, the expressed lowering of the ABP, bradycardia/tachycardia, gastrointestinal frustration.
At a concomitant use:
- with anti-hypertensive HP the risk of strengthening of anti-hypertensive effect increases;
- with beta adrenoblockers — development of the heart failure expressed to arterial hypotension;
- with aminoglycosides, furosemide, cephalosporins — risk of a renal failure;
- with Phenytoinum, phenobarbital and carbamazepine — bioavailability of a nimodipin decreases;
- with sodium Valproatum — increase of concentration of a nimodipin in blood;
- with Cimetidinum — risk of strengthening of anti-hypertensive action.
Terms of sale
At a temperature up to 25 °C.
Period of validity
Coincidence on the ATH code of the 4th level:
Actively active ingredient and the ATH code — Nimotop, Vasocorum, Niemotang, Nitopin matches.
About Nimodipin among doctors favorable. Drug Nimodipin renders positive pharmacological effects in the field of a cardiohemodynamics: reduces post-and preloads of heart muscles, weakens unstriated muscles of blood vessels, reduces contractility of a myocardium, normalizes rheological properties of blood, has anti-anginal effect.
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Nimodipin surely consult with the attending physician.